|Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer|
C Twyman-Saint Victor, AJ Rech, A Maity, R Rengan, KE Pauken, ...
Nature 520 (7547), 373-377, 2015
|Clinical use of anti‐CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells|
AJ Rech, RH Vonderheide
Annals of the New York Academy of Sciences 1174 (1), 99, 2009
|CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients|
AJ Rech, R Mick, S Martin, A Recio, NA Aqui, DJ Powell, TA Colligon, ...
Science translational medicine 4 (134), 134ra62-134ra62, 2012
|Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy|
J Li, KT Byrne, F Yan, T Yamazoe, Z Chen, T Baslan, LP Richman, JH Lin, ...
Immunity 49 (1), 178-193. e7, 2018
|Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer|
D Balli, AJ Rech, BZ Stanger, RH Vonderheide
Clinical Cancer Research 23 (12), 3129-3138, 2017
|Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer|
AJ Rech, R Mick, DE Kaplan, KM Chang, SM Domchek, RH Vonderheide
Cancer immunology, immunotherapy 59 (4), 599-607, 2010
|Lack of immunoediting in murine pancreatic cancer reversed with neoantigen|
RA Evans, MS Diamond, AJ Rech, T Chao, MW Richardson, JH Lin, ...
JCI insight 1 (14), 2016
|Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers|
EL Carpenter, R Mick, AJ Rech, GL Beatty, TA Colligon, MR Rosenfeld, ...
Clinical Cancer Research 15 (13), 4277-4287, 2009
|Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer|
A Tanimoto, S Takeuchi, S Arai, K Fukuda, T Yamada, X Roca, ST Ong, ...
Clinical Cancer Research 23 (12), 3139-3149, 2017
|Tumor immunity and survival as a function of alternative neopeptides in human cancer|
AJ Rech, D Balli, A Mantero, H Ishwaran, KL Nathanson, BZ Stanger, ...
Cancer immunology research 6 (3), 276-287, 2018
|Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency|
R Calcedo, S Somanathan, Q Qin, MR Betts, AJ Rech, RH Vonderheide, ...
Proceedings of the National Academy of Sciences 114 (7), 1655-1659, 2017
|Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer|
AJ Rech, H Dada, JJ Kotzin, J Henao-Mejia, AJ Minn, ...
Cancer research 78 (15), 4282-4291, 2018
|Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment|
AJ Rech, RH Vonderheide
Cancer discovery 3 (12), 1330-1332, 2013
|T-cell transfer therapy targeting mutant KRAS|
A Maoz, G Rennert, SB Gruber
The New England journal of medicine 376 (7), e11, 2017
|Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC).|
AJ Rech, R Mick, A Recio, A DeMichele, CK Tweed, KR Fox, ...
Journal of Clinical Oncology 28 (15_suppl), 2508-2508, 2010
|Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade|
LP Richman, RH Vonderheide, AJ Rech
Cell systems 9 (4), 375-382. e4, 2019
|Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer|
AA Kraya, KN Maxwell, B Wubbenhorst, BM Wenz, J Pluta, AJ Rech, ...
Clinical Cancer Research 25 (14), 4363-4374, 2019
|Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)|
N Markosyan, J Li, YH Sun, LP Richman, JH Lin, F Yan, L Quinones, ...
The Journal of clinical investigation 129 (9), 2019
|Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients|
C Twyman-Saint Victor, A Rech, A Maity, R Rengan, K Pauken, ...
Cancer Immunology Research 4 (1 Supplement), A056-A056, 2016
|Abstract B04: Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer|
AS Bear, AJ Rech, LP Richman, MH O'Hara, GP Linette, BM Carreno, ...
Cancer Research 79 (24 Supplement), B04-B04, 2019